Guangzhou Cellprotek Pharmaceutical Co., Ltd

Guangzhou Virotech Pharmaceutical Co., Ltd.

Guangzhou Cellprotek Pharmaceutical Ltd.

Guangzhou Cellprotek Pharmaceuticals Ltd.

Guangmei Yan

Wei Yin

Jingxia Zhang

Suizhen Lin

Pengxin Qiu

Haiyan Hu

Bingzheng Lu

Jun Hu

Wenbo Zhu

Kai Li

Yijun Huang

Jiesi Chen

Haipeng Zhang

Xiao Xiao

Yuan Lin

Jiankai Liang

Longxiang Sheng

Yuan Li

Jing Cai

Shoufang Gong

Tiandong Leng

Hanfei Sang

Shujia Zhou

Xiuhua You

Ling Li

Ning Tian

Yaqian Tan

Halyan Hu

Provided are applications of a hexokinase 2-specific inhibitor in preparing a medicament for preventing and treating acute central nervous system injury.

Hexokinase 2-specific inhibitors for use in acute central nervous system injury

Disclosed is use of 5α-androst-3β,5,6β-triol or an analogue, a deuterated compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cerebral small vessel disease in a patient. The cerebral small vessel disease is preferably cerebral microbleed. The cerebral microbleed is spontaneous cerebral microbleed, drug-related cerebral microbleed, or traumatic cerebral microbleed. The present invention demonstrates that these compounds significantly enhance the clearance of extravascular hemoglobin, and thus can be used to treat cerebral small vessel disease.

Use of compound in preparation of drug for treating cerebral small vessel disease

Disclosed is a use of 5&#x3b1;-androstane-3&#x3b2;,5,6&#x3b2;-triol, an analogue, a deuterated derivative, and a pharmaceutically acceptable salt thereof in manufacture of a medicament for the treatment of hemorrhagic stroke in a patient. The hemorrhagic stroke is intracerebral hemorrhage or subarachnoid hemorrhage.

Use of compounds in preparation of a medicament for treatment of hemorrhagic stroke

The present invention belongs to the field of biomedicine and relates to use of VCP (valosin-containing protein, VCP) inhibitor and oncolytic virus in the preparation of an anti-tumor drug. The present invention firstly discovers that VCP inhibitor can be used in the preparation of an anti-tumor synergist for oncolytic virus. Meanwhile, the present invention relates to a pharmaceutical composition comprising VCP inhibitor and oncolytic virus, a pharmaceutical kit comprising VCP inhibitor and oncolytic virus, and use of VCP inhibitor and oncolytic virus for treating tumor, especially a tumor that is not sensitive to oncolytic virus. The present invention also relates to an anti-tumor administration system, characterized in that, comprising oncolytic virus and a reagent for detecting the expression level of VCP.

Use of VCP inhibitor and oncolytic virus in the preparation of an anti-tumor drug

Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.

Use of alphavirus in preparation of antitumor drugs

Described herein is use of a Caspase activator and an oncolytic virus in the preparation of an anti-tumor drug. As described, Caspase activator can enhance the anti-tumor effect of oncolytic virus, and the combination of Caspase activator and oncolytic virus produces a significant synergistic anti-tumor effect, and demonstrates an effective therapy for the treatment of tumors that are less sensitive to other pharmaceutical treatments.

Use of IAP inhibitor and oncolytic virus in preparation of anti-tumor drug

Use of 5&#x3b1;-androstane-3&#x3b2;,5,6&#x3b2;-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5&#x3b1;-androstane-3&#x3b2;,5,6&#x3b2;-triol treatment can effectively reduce vasogenic edema of brain tissue ofcaused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.

Neuro-protective agents and uses thereof

Disclosed is the use of 5&#x3b1;-androstane-3&#x3b2;,5,6&#x3b2;-triol in preparing neuroprotective drugs. The compound has significant protective effect against neuron injuries caused by cerebral ischemia, spinal cord ischemia or hypoxia and has no obvious toxic reaction within effective dose thereof.

Use of 5&#x3b1;-androstane-3&#x3b2;,5,6&#x3b2;-triol in preparation of neuroprotective drugs

A 5&#x3b1;-androstane-3&#x3b2;,5,6&#x3b2;-triol injection and its preparation are disclosed. The injection uses hydroxypropyl-&#x3b2;-cyclodextrin as a solubilizing agent and the active ingredient is present at a weight ratio of 1-20:40-500 to the hydroxypropyl-&#x3b2;-cyclodextrin. The injection may also comprise, by weight, 1-100 parts of at least one isotonic adjusting agent, 0-200 parts of at least one freeze drying filler, and 0-2000 parts of at least one solvent. The preparation method comprises dissolving hydroxypropyl-&#x3b2;-cyclodextrin solution, 5&#x3b1;-androstane-3&#x3b2;,5,6&#x3b2;-triol and at least one additional soluble excipient in water for injection in sequence to obtain a raw injection solution, and subjecting the raw injection solution to decolorization, depyrogenation, filtration and sterilization to obtain the injection. Drying the filtrate yields a solid for injection.

5&#x3b1;-androstane-3&#x3b2;,5,6&#x3b2;-triol injection and preparation method therefor

A 5&#x3b1;-androstane-3&#x3b2;,5,6&#x3b2;-triol injection and its preparation are disclosed. The injection uses hydroxypropyl-&#x3b2;-cyclodextrin as a solubilizing agent and the active ingredient is present at a weight ratio of 1-20:40-500 to the hydroxypropyl-&#x3b2;-cyclodextrin. The injection may also comprise, by weight, 1-100 parts of at least one isotonic adjusting agent, 0-200 parts of at least one freeze drying filler, and 0-2000 parts of at least one solvent. The preparation method comprises dissolving hydroxypropyl-&#x3b2;-cyclodextrin solution, 5&#x3b1;-androstane-3&#x3b2;,5,6&#x3b2;-triol and at least one additional soluble excipient in water for injection in sequence to obtain a raw injection solution, and subjecting the raw injection solution to decolorization, depyrogenation, filtration and sterilization to obtain the injection, Drying the filtrate yields a solid for injection.

5&#x3b1;-androstane (alkyl)-3&#x3b2;, 5, 6&#x3b2;-triol injection and preparation method therefor

Disclosed is the use of 5&#x3b1;-androstane(alkyl)-3&#x3b2;,5,6&#x3b2;-triol in preparing neuroprotective drugs. The compound has significant protective effect against neuron injuries caused by cerebral ischemia, spinal cord ischemia or hypoxia and has no obvious toxic reaction within effective dose thereof.

Growing community of inventors

Guangzhou, China

Guangmei Yan